Mastic Gum

1. What conditions has Mastic Gum been studied for?

• Gastrointestinal disorders, including dyspepsia and peptic/“anti-ulcer” indications (noted as traditional use and supported by pharmacology/clinical interventions in reviews; EMA traditional-use indication for mild dyspeptic disorders).

• Inflammatory bowel disease (IBD)/colitis (clinical-trial interest noted in IBD herbal-therapy reviews; mechanistic animal study in DSS-induced colitis with an isolated constituent).

• Skin inflammation and wound healing (EMA traditional-use indication for skin inflammation/healing of minor wounds; also highlighted in reviews).

• Dyslipidemia/hyperlipidemia (rat studies with Chios mastic gum essential oil and component testing; effects on cholesterol, LDL, triglycerides).

• Hypertension (rat models: Angiotensin II–induced and DOCA-high-salt–induced hypertension).

• Type 2 diabetes (T2D)/antidiabetic targets (review summarizing in vitro and in vivo antidiabetic effects of Pistacia lentiscus).

• Oral care (listed as a demonstrated beneficial property in the ethnopharmacology/pharmacology review).

• Cancer/anticancer activity (in vitro cytotoxicity/apoptosis and cell-cycle effects in human cancer cell lines; antioxidant/phenolic correlation reported).

• General anti-inflammatory/antioxidant applications (multiple reviews describe these as central mechanisms underlying diverse proposed uses).

2. Does it work in treating those conditions? Summarize the evidence.

• Dyspepsia and minor skin inflammation/wounds: The ethnopharmacology review states that clinical interventions and trials have showed therapeutic potential, and notes that in 2015 the European Medicines Agency (EMA) recognized mastic resin as a traditional-use herbal medicinal product for mild dyspeptic disorders and skin inflammation/healing of minor wounds. This supports plausibility and traditional-use acceptance, but the studies reviewed here do not detail trial sizes, effect sizes, or comparative efficacy.

• IBD/colitis: Two IBD-focused reviews describe the clinical literature as relatively small but “promising,” and identify mastic gum among the most important/most promising herbal candidates. Mechanistic support is provided by an animal study where masticadienonic acid (MDA) (an abundant constituent) ameliorated DSS-induced acute colitis in mice, improving clinical indices (e.g., body weight, colon length, disease activity index, histology) and reducing inflammatory cytokines (TNFα, IL‑1β, IL‑6) via MAPK and NF‑κB inhibition, while improving barrier markers (ZO‑1, occludin) via Nrf2 activation and modulating gut microbiota. Translation to human IBD remains uncertain because this is an animal model and uses an isolated compound rather than whole resin.

• Dyslipidemia: In rats, mastic gum essential oil (MGO) reduced serum cholesterol and triglycerides dose-dependently, including in a detergent-induced hyperlipidemia model. The study identifies camphene as associated with the effect; in hyperlipidemic rats, camphene at 30 µg/g body weight reduced total cholesterol by 54.5%, LDL-cholesterol by 54%, and triglycerides by 34.5% (all p<0.001). In HepG2 cells, camphene lowered cellular cholesterol similarly to mevinolin, with a mechanism suggested to be independent of HMG‑CoA reductase. Evidence here is strong for an animal/preclinical signal, but not proof of clinical lipid lowering in humans.

• Hypertension: In two rat hypertension models, CMG at 220 mg/kg daily for four weeks after hypertension onset significantly lowered systolic, diastolic, and mean blood pressure. Multi-omics suggested effects on oxidative stress/endothelial dysfunction genes and upregulation of endothelial markers (e.g., Vegfa), with metabolomics indicating improved endothelial homeostasis. This is promising preclinical evidence; human antihypertensive efficacy is not established in the studies reviewed here.

• Type 2 diabetes: A review highlights multiple in vitro and in vivo antidiabetic effects of P. lentiscus acting on “many therapeutic T2D targets,” suggesting a multitarget potential. However, the study does not provide specific clinical outcomes, so effectiveness for treating T2D in humans cannot be concluded from these studies alone.

• Cancer: An in vitro study reports dose- and time-dependent cancer cell death (MTT), apoptosis-related assays (Annexin V, caspases), and cell-cycle effects, with antiproliferative efficacy correlated with polyphenolic content. This supports biological activity in cell models, but does not demonstrate clinical anticancer efficacy.

Overall, the studies support the strongest “works/benefit” claims for: (a) traditional-use indications recognized by EMA (dyspepsia; minor skin inflammation/wounds), and (b) robust preclinical signals for colitis, lipids, and blood pressure. Human efficacy beyond traditional-use indications remains incompletely established in the provided material.

3. What health benefits does it have?

• Anti-inflammatory effects: Reviews emphasize anti-inflammatory activity as a central mechanism; the MDA colitis study shows reduced systemic inflammatory cytokines (TNFα, IL‑1β, IL‑6) and inhibition of MAPK and NF‑κB signaling.

• Antioxidant/cytoprotective effects: Reviews describe antioxidant properties; in colitis, MDA activated Nrf2 signaling (a key antioxidant-response pathway). Another study quantified polyphenols/flavonoids and demonstrated free-radical scavenging (DPPH/ABTS+) alongside anticancer cell effects.

• Gut barrier support (preclinical): In DSS colitis mice, MDA restored tight junction proteins ZO‑1 and occludin, consistent with improved epithelial barrier integrity.

• Microbiome modulation (preclinical): MDA altered gut microbiota composition in DSS colitis mice, proposed as part of its benefit.

• Lipid lowering (preclinical): Mastic essential oil lowered cholesterol and triglycerides in rats; camphene produced large reductions in total cholesterol, LDL, and triglycerides in hyperlipidemic rats.

• Blood pressure lowering and endothelial/renal support (preclinical): CMG lowered blood pressure in two rat models and was associated with improved endothelial-related gene/metabolite patterns (e.g., Vegfa upregulation; reduced oxidative stress/endothelial dysfunction signals).

• Potential metabolic benefits (antidiabetic activity): A review describes multitarget antidiabetic effects of P. lentiscus in vitro/in vivo, suggesting potential relevance to glycemic control (details not provided in the study).

• Skin and wound-related benefits: EMA traditional-use recognition for skin inflammation and healing of minor wounds; also highlighted in the broader review conclusions.

• Oral care: Listed as a demonstrated beneficial property in the ethnopharmacology/pharmacology review (specific endpoints not provided in the study).

4. Does it have any downsides or side effects?

The studies reviewed here do not report specific adverse events, tolerability issues, contraindications, or drug interactions in humans.

• Evidence limitation: Several findings are based on in vitro or animal studies (colitis, lipids, hypertension, anticancer). Such studies can overestimate benefit and do not reliably predict human side-effect profiles.

• Standardization/quality concerns: The ethnopharmacology review notes the resin’s chemical complexity and a lack of commercial standards for main compounds, creating a gap in evaluating isolated components. Practically, this implies that different products could vary in composition and potentially in effects and tolerability.

• Dose translation uncertainty: Some preclinical studies used defined doses (e.g., 220 mg/kg/day in rats for hypertension; camphene dosing in lipid studies). Human-equivalent dosing and safety at effective exposures are not established in these studies.

Because adverse effects are not described here, no evidence-based claim can be made from these studies alone about whether mastic gum commonly causes side effects, or what they might be.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

No pharmacogenomic findings are reported in the studies reviewed here.

• No gene-variant response data: None of the studies evaluate whether specific human genetic variants (e.g., in inflammatory pathways, lipid metabolism, drug-metabolizing enzymes) alter response or risk.

• Mechanistic signals are not pharmacogenomics: The hypertension study reports RNA sequencing changes (e.g., oxidative stress/endothelial dysfunction genes; Vegfa expression changes), but this reflects treatment-associated gene expression in rats, not inherited genetic variation predicting benefit or harm in humans.

References

1. Traditional uses, phytochemistry and pharmacology of Chios mastic gum (Pistacia lentiscus var. Chia, Anacardiaceae): A review.
   Vasiliki K Pachi, Eleni V Mikropoulou, Petros Gkiouvetidis, Konstantinos Siafakas, Aikaterini Argyropoulou, Apostolis Angelis, Sofia Mitakou, Maria Halabalaki (2020) - Journal of ethnopharmacology
2. Herbal and plant therapy in patients with inflammatory bowel disease.
   Aikaterini Triantafyllidi, Theodoros Xanthos, Apostolos Papalois, John K Triantafillidis (2015) - Annals of gastroenterology
3. Pistacia lentiscus: Phytochemistry and Antidiabetic Properties
   Sonia Floris, Amalia Di Petrillo, Francesca Pintus, Giovanna Lucia Delogu (2024)
4. Overview of Chios Mastic Gum (
   Stergios Soulaidopoulos, Aikaterini Tsiogka, Christina Chrysohoou, Emilia Lazarou, Konstantinos Aznaouridis, Ioannis Doundoulakis, Dimitra Tyrovola, Dimitris Tousoulis, Konstantinos Tsioufis, Charalambos Vlachopoulos, George Lazaros (2022) - Nutrients
5. Masticadienonic acid from Chios mastic gum mitigates colitis in mice via modulating inflammatory response, gut barrier integrity and microbiota.
   Hao Cui, Xia Li, Xue-Rui An, Wei Liu, Tao Yuan (2023) - Phytomedicine : international journal of phytotherapy and phytopharmacology
6. Camphene, a plant-derived monoterpene, reduces plasma cholesterol and triglycerides in hyperlipidemic rats independently of HMG-CoA reductase activity.
   Ioanna Vallianou, Nikolaos Peroulis, Panayotis Pantazis, Margarita Hadzopoulou-Cladaras (2011) - PloS one
7. Favorable results from the use of herbal and plant products in inflammatory bowel disease: evidence from experimental animal studies.
   John K Triantafillidis, Aikaterini Triantafyllidi, Constantinos Vagianos, Apostolos Papalois (2016) - Annals of gastroenterology
8. Phytochemical analysis and antioxidant and anticancer activities of mastic gum resin from
   Heshu Sulaiman Rahman (2018) - OncoTargets and therapy
9. Anti-inflammatory activity of Chios mastic gum is associated with inhibition of TNF-alpha induced oxidative stress.
   Angelike Triantafyllou, Alfiya Bikineyeva, Anna Dikalova, Rafal Nazarewicz, Stamatios Lerakis, Sergey Dikalov (2011) - Nutrition journal
10. Mastic (Pistacia lentiscus) gum and oral health: a state-of-the-art review of the literature.
    Maram Ali M Alwadi, Amrita Sidhu, Méghit Boumédiène Khaled, Basil H Aboul-Enein (2023) - Journal of natural medicines
11. Antioxidant and Anti-Inflammatory Properties of Mastiha: A Review of Preclinical and Clinical Studies.
    Efstathia Papada, Andriana C Kaliora (2019) - Antioxidants (Basel, Switzerland)
12. Camphene, a Plant Derived Monoterpene, Exerts Its Hypolipidemic Action by Affecting SREBP-1 and MTP Expression.
    Ioanna Vallianou, Margarita Hadzopoulou-Cladaras (2016) - PloS one
13. Effects of Chios mastic gum on cholesterol and glucose levels of healthy volunteers: A prospective, randomized, placebo-controlled, pilot study (CHIOS-MASTIHA).
    Athanasios Kartalis, Matthaios Didagelos, Ioannis Georgiadis, Georgios Benetos, Nikolaos Smyrnioudis, Haralambos Marmaras, Petros Voutas, Christina Zotika, Stefanos Garoufalis, Georgios Andrikopoulos (2016) - European journal of preventive cardiology
14. Human Adenocarcinoma Cell Line Sensitivity to Essential Oil Phytocomplexes from Pistacia Species: a Multivariate Approach.
    Alessandro Buriani, Stefano Fortinguerra, Vincenzo Sorrenti, Stefano Dall'Acqua, Gabbriella Innocenti, Monica Montopoli, Daniela Gabbia, Maria Carrara (2017) - Molecules (Basel, Switzerland)
15. Mastiha (Pistacia lentiscus) Improves Gut Microbiota Diversity, Hepatic Steatosis, and Disease Activity in a Biopsy-Confirmed Mouse Model of Advanced Non-Alcoholic Steatohepatitis and Fibrosis.
    Aimo Kannt, Efstathia Papada, Claire Kammermeier, Giuseppe D'Auria, Nuria Jiménez-Hernández, Martin Stephan, Uwe Schwahn, Andreas Nygaard Madsen, Mette Viberg Østergaard, George Dedoussis, M Pilar Francino (2019) - Molecular nutrition & food research
16. "Pistacia lentiscus L." reduces the infarct size in normal fed anesthetized rabbits and possess antiatheromatic and hypolipidemic activity in cholesterol fed rabbits.
    Ioanna Andreadou, Sofia Mitakou, Sotirios Paraschos, Panagiotis Efentakis, Prokopios Magiatis, Loukas Kaklamanis, Maria Halabalaki, Leandros Skaltsounis, Efstathios K Iliodromitis (2016) - Phytomedicine : international journal of phytotherapy and phytopharmacology
17. Chios Mastic Gum: A Promising Phytotherapeutic for Cardiometabolic Health.
    Sarah A Blomquist, Maria Luz Fernandez (2024) - Nutrients
18. Hydroxyethyl Cellulose Promotes the Mucin Retention of Herbal Extracts Active against
    Shiri Livne, Sapir Simantov, Arkadi Rahmanov, Uziel Jeffet, Nir Sterer (2022) - Materials (Basel, Switzerland)

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.